All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
GSE.6H9 and GSE.20D11 are the first insulin B:9–23–reactive CD4 T cells identified from inflamed pancreatic islets of patients with type 1 diabetes. GSE.20D11, was identified from a different organ donor (donor 6342) and responded to B:9–23 presented by DQ8. The levels of response to B:9–23 were dose dependent but were not as robust as that by a T-cell transductant reacting with a neoantigen or deamidated α-gliadin, and were several orders of magnitude stronger than the GSE.8E3 response to C:19–35. The minimum requirement for both GSE.6H9 and GSE.20D11 was insulin B-chain amino acids 12–22.
There are currently no customer reviews or questions for Human anti-Insulin B T cell receptor (20D11), pCDTCR1 (TCR-YC0572). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION